← Leaderboards
Mary L Vance
University Of Virginia Charlottesville
$1,068,571
Attributed
$1,068,571
Total exposure
17
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $60.6K · FY2005–10$100K$75K$50K$25K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$1,068,571 · 17
By mechanism
M01$1,068,571 · 17
Top collaborators
No co-investigators on record.
Most similar at University Of Virginia Charlottesville
Same institution · by research overlap
- Michael O Thorner$7,721,062
- Fraydoon Rastinejad$13,380,437
- Alan D. Rogol$2,440,436
- Bruce D Gaylinn$409,344
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchSomatotropinHuman SubjectInsulinlike Growth FactorHuman Therapy EvaluationAcromegalyHormone Regulation /Control MechanismEndocrine Disorder ChemotherapyHormone TherapyDrug Screening /EvaluationHormone InhibitorHormone ReceptorSomatostatinMetabolismHormone MetabolismPolyethylene GlycolsOctreotideOperative Surgical ProceduresPituitary-Dependent Cushing&AposPituitary NeoplasmsHydrocortisoneFundingAftercareGrant
Grant awards (42)
PREOPERATIVE BEXAROTENE TREATMENT FOR CUSHING'S DISEASE$20,046
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: EFFECT OF GROWTH HORMONE TREATMENT ON RECOVERY FROM CUSHING'S DI$8,019
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: EFFECT OF GROWTH HORMONE TREATMENT ON RECOVERY FROM CUSHING'S DI$18,522
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: EFFECT OF GROWTH HORMONE TREATMENT ON RECOVERY FROM CUSHING'S DI$46,535
M01 · FY2008 · RR · contact PI
EFFECT OF GROWTH HORMONE TREATMENT ON RECOVERY FROM CUSHING'S DISEASE$60,581
M01 · FY2007 · RR · contact PI
EFFECT OF GROWTH HORMONE TREATMENT ON RECOVERY FROM CUSHING'S DISEASE$39,824
M01 · FY2006 · RR · contact PI
PEGVISOMANT; SANDOSTATIN LAR; PEGVISOMANT PLUS SANDOSTATIN LAR IN ACROMEGALY$10,723
M01 · FY2006 · RR · contact PI
THE EFFICACY AND SAFETY; PEGVISOMANT VSASANDOSTATIN LAR$1,533
M01 · FY2006 · RR · contact PI
PEGVISOMANT;SANDOSTATIN LAR;PEGVISOMANT PLUS SANDOSTATIN LAR IN ACROMEGALY$26,784
M01 · FY2005 · RR
EFFECT OF GROWTH HORMONE TREATMENT ON RECOVERY FROM CUSHING'S DISEASE$20,483
M01 · FY2005 · RR
THE EFFICACY AND SAFETY;PEGVISOMANT VS SANDOSTATIN LAR$9,453
M01 · FY2005 · RR
SURGICAL DEBULKING;RESPONSE TO OCTREOTIDE LAR, ACROMEGALY$3,150
M01 · FY2005 · RR
Pegvisomant and Sandostatin LAR in Acromegaly$8,831
M01 · FY2004 · RR
Efficacy And Safety;Pegvisomant Vs Sandostatin LAR$2,209
M01 · FY2004 · RR
B2036-PEG IN TREATMENT OF ACROMEGALY$48,533
M01 · FY2002 · RR
OPEN LABEL TRIAL OF B2036 PEG IN TREATMENT OF ACROMEGALY$48,533
M01 · FY2002 · RR
LANREOTIDE IN ACROMEGALY$48,533
M01 · FY2002 · RR
SANDOSTATIN LAR$48,533
M01 · FY2002 · RR
DOUBLE BLIND, PLACEBO CONTROLLED TRIAL OF B2036 PEG IN ACROMEGALY$48,533
M01 · FY2002 · RR
METABOLIC EFFECTS OF GROWTH HORMONE IN GH DEFICIENT ADUL$48,533
M01 · FY2002 · RR
24 HR URINARY FREE CORTISOL EXCRETION IN REPONSE TO DEXAMETHASONE IN AFRICAN AMER$48,533
M01 · FY2002 · RR
OPEN LABEL TRIAL OF B2036 PEG IN TREATMENT OF ACROMEGALY$48,533
M01 · FY2001 · RR
DOUBLE BLIND, PLACEBO CONTROLLED TRIAL OF B2036 PEG IN ACROMEGALY$48,533
M01 · FY2001 · RR
SANDOSTATIN LAR$48,533
M01 · FY2001 · RR
LANREOTIDE IN ACROMEGALY$48,533
M01 · FY2001 · RR
24 HR URINARY FREE CORTISOL EXCRETION IN REPONSE TO DEXAMETHASONE IN AFRICAN AMER$48,533
M01 · FY2001 · RR
METABOLIC EFFECTS OF GROWTH HORMONE IN GH DEFICIENT ADUL$48,533
M01 · FY2001 · RR
B2036-PEG IN TREATMENT OF ACROMEGALY$48,533
M01 · FY2001 · RR
DOUBLE BLIND, PLACEBO CONTROLLED TRIAL OF B2036 PEG IN ACROMEGALY$28,104
M01 · FY2000 · RR
SANDOSTATIN LAR$28,104
M01 · FY2000 · RR
LANREOTIDE IN ACROMEGALY$28,104
M01 · FY2000 · RR
OPEN LABEL TRIAL OF B2036 PEG IN TREATMENT OF ACROMEGALY$28,104
M01 · FY2000 · RR
B2036-PEG IN TREATMENT OF ACROMEGALY$0
M01 · FY2000 · RR
METABOLIC EFFECTS OF GROWTH HORMONE IN GH DEFICIENT ADUL$0
M01 · FY2000 · RR
METABOLIC EFFECTS OF GROWTH HORMONE IN GH DEFICIENT ADUL$0
M01 · FY2000 · RR
DOUBLE BLIND, PLACEBO CONTROLLED TRIAL OF B2036 PEG IN ACROMEGALY$0
M01 · FY2000 · RR
B2036-PEG IN TREATMENT OF ACROMEGALY$0
M01 · FY2000 · RR
24 HR URINARY FREE CORTISOL EXCRETION IN REPONSE TO DEXAMETHASONE IN AFRICAN AMER$0
M01 · FY2000 · RR
24 HR URINARY FREE CORTISOL EXCRETION IN REPONSE TO DEXAMETHASONE IN AFRICAN AMER$0
M01 · FY2000 · RR
OPEN LABEL TRIAL OF B2036 PEG IN TREATMENT OF ACROMEGALY$0
M01 · FY2000 · RR
LANREOTIDE IN ACROMEGALY$0
M01 · FY2000 · RR
SANDOSTATIN LAR$0
M01 · FY2000 · RR